blood-brain barrier constraints to successful monoclonal antibody-based therapies of brain tumors may have been overestimated since antibody conjugates have plasma half-lives longer than dt , and the permeability of n417d tumors to dt is equal to or less than the permeability of other experimental tumors to large proteins .
C0027651
tumors
C0027659
experimental tumors